胃癌靶向治疗药物新进展  

New progress of targeted drug in gastric cancer

作　　者：戴广海[1] 郭晓川[1] 

机构地区：[1]解放军总医院肿瘤内二科,北京100853

出　　处：《中国药物应用与监测》2014年第5期259-262,共4页Chinese Journal of Drug Application and Monitoring

基　　金：吴阶平医学基金会临床科研专项资助课题(320.6750.1233)

摘　　要：胃癌是我国高发的消化道恶性肿瘤,总体预后不佳。近些年,虽然晚期胃癌患者生活质量得到了一定的改善以及生存期的延长,但晚期胃癌患者5年生存率较低,化疗的疗效也很局限。随着分子生物学的发展,人们对于胃癌的发生发展有了深入的认识,胃癌治疗已进入个体化靶向治疗的新时代,靶向药物通过与癌症发生、肿瘤生长所必需的特定分子靶点的作用来阻止癌细胞的生长。许多大型胃癌临床试验评估了靶向药物在晚期胃癌患者中的疗效及安全性。及早筛查靶向治疗相关生物标志物,及早分类并有的放矢开展治疗,将成为今后胃癌规范治疗的主要方向。Gastric cancer is a high-incidence gastrointestinal malignant tumour in China, and the overall prognosis is poor. Recently, although the quality of life and the survival of patients with advanced gastric cancer have been improved, the 5-year survival rate is still low and the efficacy of chemotherapy is also very limited. With the development of molecular biology, there is a thorough understanding of the genesis and development of gastric cancer. At present, the treatment of gastric cancer has entered a new era of individual targeted therapy, targeted drugs can prevent the growth of cancer cells by binding specific molecular targets which are essential for the development of cancer. Many large clinical trials had assessed the efficacy and safety of targeted drugs in patients with gastric cancer. Screening targeted therapy-related biomarkers early and targeted therapy according to status of biomarkers will become the main direction of standard treatment of gastric cancer.

关 键 词：胃癌 靶向药物 新进展 

分 类 号：R735.2[医药卫生—肿瘤]